The correct way to take baricitinib/alemin and usage guide

Baricitinib (Baricitinib) is an oral small molecule selective JAK1/JAK2 inhibitor that is widely used in the treatment of immune-related diseases. Its ability to precisely inhibit the JAK signaling pathway enables it to demonstrate unique efficacy in rheumatoid arthritis, alopecia areata, specific viral infections and other diseases. In clinical application, there are significant differences in dosage and usage for different diseases, so mastering standardized medication guidelines is crucial to ensure efficacy and safety.

In the treatment of rheumatoid arthritis (RA), baricitinib is usually administered at 2 mg orally once daily. The drug can be used as a monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) to enhance anti-inflammatory effects and improve joint function. Clinical studies have shown that regular medication can effectively reduce joint swelling and pain and improve patients' quality of life.

In the adjuvant treatment of COVID-19, the dose of baricitinib is slightly higher, 4mg orally once daily and the treatment cycle does not exceed 14 days. Its mechanism of action is to inhibit the excessive immune response caused by viral infection, especially the release of inflammatory factors mediated by the JAK-STAT pathway, thereby reducing the risk of inflammatory storm. This therapy is mainly for moderate to severe patients and needs to be combined with antiviral or other standard treatment options.

Alopecia Areata (Alopecia Areata) is one of the newly approved indications for baricitinib in recent years. For patients with hair loss, the recommended starting dose is 2 mg orally once daily. If the clinical response is not obvious, it can be increased to 4mg daily. For patients with almost complete or complete hair loss, or with a large number of eyebrows and eyelashes falling off, the starting dose is 4 mg per day; after achieving sufficient efficacy, it can be gradually reduced to 2 mg per day to maintain the effect. Clinical data shows that baricitinib blocks immune cell attacks on hair follicles by inhibiting the JAK signaling pathway, thereby promoting hair regeneration and recovery of the growth cycle.

Reference materials:https://go.drugbank.com/drugs/DB11817